RT Journal Article
T1 A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases.
A1 Zozaya, Néboa
A1 Arrizubieta Basterrechea, Maria Iciar
A1 Bollo, Elena
A1 Castellví, Iván
A1 Espín, Jaime
A1 Ortego, Norberto
A1 Poveda-Andrés, José Luis
A1 Rodríguez Portal, José Antonio
A1 Rivero, Agustín
A1 Marcos-Rodríguez, José Antonio
A1 Verde, Luis
K1 Interstitial lung diseases
K1 Multi-criteria decision analysis
K1 Pulmonary fibrosis
K1 Systemic sclerosis
AB Our aim was to assess the value of nintedanib for non-idiopathic progressive fibrosing interstitial lung disease (non-IPF PF-ILD) and systemic sclerosis-associated ILD (SSc-ILD) in the Spanish context, using a multi-criteria decision analysis (MCDA). Following an adaptation of the Evidence and Value: Impact on DEcision Making (EVIDEM) MCDA methodology, the estimated value of nintedanib was obtained by means of an additive linear model that combined individual weights (100-points distribution) of criteria with the individual scoring of nintedanib in each criterion for every indication, assigned by a multidisciplinary committee of twelve clinicians, patients, pharmacists, and decision-makers. To assess the reproducibility, an alternative weighting method was applied, as well as a re-test of weights and scores at a different moment of time. The experts committee recognized nintedanib as an intervention with a positive value contribution in comparison to placebo for the treatment of non-IPF PF-ILD (0.50 ± 0.16, on a scale from -1 to 1) and SSc-ILD (0.40 ± 0.12), diseases which were considered as very severe and with high unmet needs. The drug was perceived as a treatment that provides an added therapeutic benefit for patients (0.06-0.07), given its proven clinical efficacy (0.05-0.06), slight improvements in patient-reported outcomes (0.01-0.02), and similar safety profile than placebo (-0.04-0.00), which will likely be positioned as a recommended therapy in the next clinical practice guidelines updates. Under this increasingly used methodology, nintedanib has shown to provide a positive value estimate for non-IPF PF-ILD and SSc-ILD when compared to placebo in Spain.
PB Cambridge University Press
YR 2022
FD 2022-08-01
LK http://hdl.handle.net/10668/22578
UL http://hdl.handle.net/10668/22578
LA en
NO Zozaya N, Arrizubieta Basterrechea MI, Bollo E, Castellví I, Espín J, Ortego N, et al. A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases. Int J Technol Assess Health Care. 2022 Aug 1;38(1):e64.
DS RISalud
RD Apr 7, 2025